



Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown, MA 02472
P: (617) 607-0800

February 5, 2024

VIA EDGAR

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Enanta Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-275723
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Act"), Enanta Pharmaceuticals, Inc. (the "Registrant") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-275723), as amended (the "Registration Statement"), so that it may become effective at 4:00 pm Eastern time on February 8, 2024, or as soon thereafter as practicable, or at such other time as the Registrant or its outside counsel, Foley Hoag LLP, requests by telephone that such Registration Statement be declared effective. The Registrant hereby confirms that it is aware of its responsibilities under the Act.

It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Ryan Rourke Reed of Foley Hoag LLP, by telephone at (617) 832-1181 or by email at rrourkereed@foleyhoag.com.

[Remainder of this page intentionally left blank]

Very truly yours,

ENANTA PHARMACEUTICALS, INC.

By: /s/ Paul J. Mellett

Name: Paul J. Mellett

Title: Chief Financial and Administrative Officer

[Signature Page to Acceleration Request]